Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.77 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.70 |
| ▸ | USP2 | O75604 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.66 |
| ▸ | OSBP | P22059 | 1/20 | 0.66 |
| ▸ | RORC | P51449 | 1/20 | 0.66 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.66 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.64 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3953202 | 1.00 | POLA1 (0.77) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL3953206 | 1.00 | POLA1 (0.77) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL27319672 | 1.00 | POLA1 (0.77) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL5386706 | 1.00 | POLA1 (0.77) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL3954234 | 0.98 | POLA1 (0.77) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL3954232 | 0.98 | POLA1 (0.77) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL25351944 | 0.98 | POLA1 (0.77) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL2134010 | 0.98 | POLA1 (0.77) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL27319635 | 0.98 | POLA1 (0.77) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL11426770 | 0.98 | POLA1 (0.75) | POLA1CYP46A1USP2LMNAABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109732-A1 | LIPID AMINES | MODERNATX INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250235531-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MODERNATX, INC. (US) | 2025-07-24 | — | — | US | disclosed |
| WO-2023154818-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MODERNATX, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023076598-A1 | LIPID AMINES | MODERNATX, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250235531-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MUC1, RNMT, FABP2 | POLA1 1481/4885CYP46A1 1475/4885USP2 1671/4885 |
| US-20260109732-A1 | LIPID AMINES | LDLR, NPC1, PHOSPHO1 | POLA1 2294/4885CYP46A1 156/4885USP2 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.